LVM Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

LVM Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-49,306	Closed	-$3.76M	–	148
2023 Q1	$3.76M	Sell	49,306 -2,350	-5%	-$195K	0.52%	45
2022 Q4	$4.29M	Sell	51,656 -7,132	-12%	-$577K	0.62%	45
2022 Q3	$4.66M	Sell	58,788 -6,290	-10%	-$530K	0.71%	41
2022 Q2	$4.83M	Sell	65,078 -12,000	-16%	-$901K	0.7%	41
2022 Q1	$6.93M	Buy	77,078 +5,447	+8%	+$503K	0.92%	37
2021 Q4	$8.02M	Buy	71,631 +1,271	+2%	+$153K	1.07%	34
2021 Q3	$8.85M	Buy	70,360 +1,921	+3%	+$247K	1.33%	28
2021 Q2	$9.27M	Buy	68,439 +2,325	+4%	+$306K	1.41%	27
2021 Q1	$8.97M	Sell	66,114 -752	-1%	-$113K	1.45%	27
2020 Q4	$9.41M	Sell	66,866 -710	-1%	-$90.9K	1.59%	25
2020 Q3	$7.53M	Buy	67,576 +6,180	+10%	+$693K	1.46%	26
2020 Q2	$6.87M	Buy	+61,396	New	+$6.05M	1.41%	27

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

LVM Capital Management's XBI Position: Q2 2023 in Review

LVM Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2023, closing a stake of 49,306 shares — an estimated $3.76M sold.

LVM Capital Management first reported a position in XBI in Q2 2020 and held it in 12 quarters. The position peaked at $9.41M in Q4 2020. 712 funds tracked by Wall St. Rank hold XBI as of Q2 2023.

LVM Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2023 after selling out during the quarter.
LVM Capital Management sold 49,306 State Street SPDR S&P Biotech ETF shares in Q2 2023, an estimated $3.76M.
LVM Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and held it in 12 quarters.
LVM Capital Management's State Street SPDR S&P Biotech ETF position peaked at $9.41M in Q4 2020.
712 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2023.

Based on LVM Capital Management's 13F filing for Q2 2023, filed 7 Jul 2023.